Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope
ABSTRACTMimotope, a kind of peptide vaccine, is developed to bind natural receptor and inhibit the downstream signaling. We have demonstrated that the vaccination of Tocilizumab mimotopes could alleviate the renal fibrosis by interfering with both IL-6 and ferroptosis signaling. However, the effect of the vaccination of Tocilizumab mimotopes on the fibroblast was not investigated in previous study. Thus, we sought to explore the changes in the fibroblast induced by the Tocilizumab mimotopes vaccination. Bleomycin instillation was performed to construct the pulmonary fibrosis model after the immunization of Tocilizumab mimotopes. Lung histological analysis showed that the Tocilizumab mimotopes could significantly reduce the maladaptive repairment and abnormal remodeling. Immunoblotting assay and fluorescence staining showed that Immunization with the Tocilizumab mimotopes reduces the accumulation of fibrosis-related proteins. High level of lipid peroxidation product was observed in the animal model, while the Tocilizumab mimotopes vaccination could reduce the generation of lipid peroxidation product. Mechanism analysis further showed that Nrf-2 signaling, but not GPX-4 and FSP-1 signaling, was upregulated, and reduced the lipid peroxidation. Our results revealed that in the BLM-induced pulmonary fibrosis, high level of lipid peroxidation product was significantly accumulation in the lung tissues, which might lead to the occurrence of ferroptosis. The IL-6 pathway block therapy could inhibit lipid peroxidation product generation in the lung tissues by upregulating the Nrf-2 signaling, and further alleviate the pulmonary fibrosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Human Vaccines & Immunotherapeutics - 20(2024), 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jin Guo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Fibroblast |
|---|
| doi: |
10.1080/21645515.2024.2319965 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ092943071 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ092943071 | ||
| 003 | DE-627 | ||
| 005 | 20240413165710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2024.2319965 |2 doi | |
| 035 | |a (DE-627)DOAJ092943071 | ||
| 035 | |a (DE-599)DOAJ2a63ffc043034fcba61cea339f955bfc | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Jin Guo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACTMimotope, a kind of peptide vaccine, is developed to bind natural receptor and inhibit the downstream signaling. We have demonstrated that the vaccination of Tocilizumab mimotopes could alleviate the renal fibrosis by interfering with both IL-6 and ferroptosis signaling. However, the effect of the vaccination of Tocilizumab mimotopes on the fibroblast was not investigated in previous study. Thus, we sought to explore the changes in the fibroblast induced by the Tocilizumab mimotopes vaccination. Bleomycin instillation was performed to construct the pulmonary fibrosis model after the immunization of Tocilizumab mimotopes. Lung histological analysis showed that the Tocilizumab mimotopes could significantly reduce the maladaptive repairment and abnormal remodeling. Immunoblotting assay and fluorescence staining showed that Immunization with the Tocilizumab mimotopes reduces the accumulation of fibrosis-related proteins. High level of lipid peroxidation product was observed in the animal model, while the Tocilizumab mimotopes vaccination could reduce the generation of lipid peroxidation product. Mechanism analysis further showed that Nrf-2 signaling, but not GPX-4 and FSP-1 signaling, was upregulated, and reduced the lipid peroxidation. Our results revealed that in the BLM-induced pulmonary fibrosis, high level of lipid peroxidation product was significantly accumulation in the lung tissues, which might lead to the occurrence of ferroptosis. The IL-6 pathway block therapy could inhibit lipid peroxidation product generation in the lung tissues by upregulating the Nrf-2 signaling, and further alleviate the pulmonary fibrosis. | ||
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 4 | |a lipid peroxidation | |
| 650 | 4 | |a fibroblast | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a mimotope | |
| 650 | 4 | |a IL-6 | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Lin Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Haoming Song |e verfasserin |4 aut | |
| 700 | 0 | |a Li Bai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Human Vaccines & Immunotherapeutics |d Taylor & Francis Group, 2022 |g 20(2024), 1 |w (DE-627)DOAJ000147656 |x 2164554X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:1 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/21645515.2024.2319965 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/2a63ffc043034fcba61cea339f955bfc |z kostenfrei |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/10.1080/21645515.2024.2319965 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2164-5515 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2164-554X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 1 | ||